Posted on May 22, 2023
Howdy, g’day and welcome.
We have a potential 9900% winner on offer today via Amgen Inc. (NASDAQ:AMGN), developers of a number of therapeutic applications that kill you even as they heal.
But more on those blokes in a just a moment.
First, we’ve got some cash on the table.
It’s our February 23rd TPX trade, and it’s is now ripe for closure.
You’ll recall that on March 20th we shut down the trade’s long June 16th PUT spread, but left the short CALL open. That gave us an overall credit of $2.20.
And today, we finish the job.
We’re buying back the June 16th 40 CALL for $0.60 and walking with $1.60 on just a nickel expended.
And that’s a mighty fine 3100%.
[N.B., we had originally forecast a 4300% take on the trade, fully expecting the short CALL to expire worthless. Alas, we’ll have to suffice with a mere 3100%…]
And now we return to the narcotic portion of our show.
AMGN claims that it “focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience therapeutics”.
But we all know that’s not true.
What they focus on, in fact, is making lots of money from people who’ve been boondoggled into thinking that disease and ill health are a natural part of life.
Let’s first look at some numbers.
In other words, AMGN’s got inferior bone health and its stock price suffers from inflammation.
In the real world, regulators are prohibiting the company from proceeding with its $28 billion takeover of Horizon Therapeutics, and that (along with the company’s increasingly unmanageable debt) is making investors nervous.
Many believe AMGN will have to issue a new round of shares to pay off the near $50 billion in liabilities it now possesses.
May the G-d of Israel deliver all our enemies into our hands!
With kind regards,
Hugh L. O’Haynew